Advertisement

Organisation › Details
Cell Signaling Technology (CST) (Group)
Cell Signaling Technology, Inc. is dedicated to delivering the world's highest quality research, diagnostic, and therapeutic products to accelerate biological understanding and enable personalized medicine. Through its proprietary monoclonal antibody technology, NG-XMT™, and PTMScan® proteomics technology, CST continues to be at the forefront of applied systems biology research, promoting greater understanding of biochemical aberrations that underlie critical diseases, including cancer. CST has made significant discoveries in cancer research through its internal research group, and from this has built an intellectual property portfolio around biomarkers relevant to non-small cell lung cancer. *
![]() |
Start | 1999-01-01 splitoff |
Today | Cell Signaling Technology Inc. (CST) | |
![]() |
Industry | antibody |
Industry 2 | proteomic technology | |
City | 01923 Danvers, MA | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | D: 101 to 500 (2013-06-08) |
* Document for »About Section«: | ||
Record changed: 2024-09-23 |
Advertisement

More documents for Cell Signaling Technology (CST) (Group)
- [1] Bioké (Cell Signaling Technology Europe B.V.). (9/16/24). "Press Release: Bioké and e-Blot Announce a Distribution Agreement in the European Region". Leiden....
- [2] Bioké (Cell Signaling Technology Europe B.V.). (1/14/19). "Press Release: Bioké and OLS Omni Life Science Announce a Distribution Agreement for the BeNeLux Countries". Leiden....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top